RZLT SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Core Viewpoint - Rezolute, Inc. has faced significant stock price decline following disappointing results from its Phase 3 clinical trial for its lead drug candidate, ersodetug, which did not meet primary and key secondary endpoints [5][6]. Group 1: Company Overview - Rezolute, Inc. is publicly traded on NASDAQ under the ticker RZLT [4]. - The company is focused on developing treatments for congenital hyperinsulinism [5]. Group 2: Clinical Trial Results - The Phase 3 sunRIZE clinical trial for ersodetug reported that the highest dose did not show statistically significant reductions in hypoglycemia events compared to placebo [5]. - The trial's failure to meet both primary and key secondary endpoints has led to investor disappointment [5]. Group 3: Stock Performance - On December 11, 2025, Rezolute's stock price plummeted from approximately $10.94 to an intraday low of around $0.90, marking an approximate 85-90% drop [6]. - Trading was halted under Nasdaq's volatility controls due to the drastic decline in stock price [6].